Childhood Cancer
Conditions
Interventions
None listed
Sponsors
Princess Maxima Center
Eligibility
Inclusion criteria
Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria; We will include 2 groups of CC patients in our study: 1) 100 CC patients receiving anthracyclines as part of their cancer treatment in the Princess Máxima Center for Pediatric Oncology (group 1). 2) A subgroup of 30 CC patients aged > 8 years, diagnosed with HL, ES, OS or STS, receiving anthracyclines as part of their cancer treatment and will undergo MRI evaluation as part of their tumor response evaluation. (group 2). All children and/or their parents will be asked for informed consent for cardiac screening with the described multimodality approach using echocardiography, ECG and future cardiac blood biomarkers and genetic testing. Patients who meet the inclusion criteria for group 2, will be asked for an additional informed consent to also undergo cardiac MRI.
Exclusion criteria
Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: Exclusion criteria are children with severe comorbidity (being too sick for evaluation), history of thoracic radiation or chemotherapy for other malignancies, general contraindications for MRI for the patients in the MRI study group. Patients who need anaesthesia for MRI scanning will be excluded from the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Echocardiography systolic dysfunction at pretreatment, 3-4 months after start treatment and 1-year post start treatment: •A change in left ventricular ejection fraction (EF) (echocardiography), defined as a decline in EF of >10% from baseline measurement or a decrease to a value 10% from baseline measurement or to a value 15% decline in GLS from baseline measurement 2.Presence of myocardial fibrosis (MRI) at pretreatment, 3-4 months after start treatment and 1-year post start treatment expressed by increased myocardial T1 values, ECV (extracellular volume), and/or delayed enhancement. | — |
Contacts
Public ContactAnnelies Mavinkurve-Groothuis
Princess Maxima Center for pediatric oncology
Outcome results
None listed